DBV Technologies has filed for a $245 million (€224 million) share offering. Almost 40% of the mighty sum is earmarked for development of treatments for milk and peanut allergies, which the French biotech is trying to hustle to market ahead of its rivals' competitors.
In another demonstration of the big bets being made on reengineering T cells to attack cancer, Oxford, U.K.-based Immunocore has come up with a monster $320 million venture round designed to push the pipeline well past positive early stage data for its lead therapy.
Autifony Therapeutics has returned to its investors for £8 million ($12 million) to fund a broadening of its R&D ambitions. The company, which spun out of GlaxoSmithKline with an age-related hearing loss program in 2011, is now going after schizophrenia.
AC Immune has picked up a milestone payment in its CHF 400 million ($421 million) anti-tau collaboration with Genentech. The Roche subsidiary handed over the cash after selecting a tau-targeting antibody developed in the collaboration to advance toward the clinic.
The United Kingdom has put Cambridge at the heart of its £50 million ($78 million) push into precision medicines. Cambridge is to host the headquarters of the precision medicine network, from which a team will coordinate regional centers to support the advance of targeted therapies through the clinic and into real-world use.
Imperial Innovations has returned to the European Investment Bank for cash, signing off on a £50 million ($78 million) loan just two years after it tapped the same source for £30 million. The need to double-dip in the EIB funding font arose after Imperial Innovations stepped up its rate of investment.
Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
Bristol-Myers Squibb is teaming up with researchers at the Medical University of South Carolina to shed some light on the root causes of fibrotic disease, planning translational studies on a handful of ailments with hopes of spotlighting new treatments.
Generally, multibillion-dollar biotech deals these days come with a considerable amount of light scolding from analysts fretting over the cost as valuations surge. Downside remarks tend to caution against looking for a higher share price, and one analyst at least raises the prospect that the bidding war may not be over. Here's a selection of notable comments this morning.
Sanofi, adjusting to life under new leadership, is planning to split up its business into 5 standalone segments, a move CEO Olivier Brandicourt said will help the company follow through on its promise to launch 18 new drugs over the next 5 years.
Japanese drugmaker Takeda is angling to win FDA approval for its lead cancer asset, an oral treatment for blood malignancies that is key to the company's future in oncology.
By all accounts, the bidding war for Receptos was intense. But for Celgene CEO Bob Hugin and his go-to deals chief George Golumbeski, strategically this was exactly the right time to clinch a $7.2 billion buyout deal for the biotech and its lead drug ozanimod. And after they add this latest late-stage program to the pipeline, there are still more deals to be done.
Celgene is trading $7.2 billion in cash for Receptos and its Phase III autoimmune treatment, building on some recent success in the field.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it's already made a $50 million anchor investment in.
Sarepta, jockeying with rival BioMarin to commercialize a treatment for Duchenne muscular dystrophy, is looking to buy up complementary assets to fortify its position. But the company's better-funded competitor believes its long history in rare disease R&D will give it a leg up as the pair move toward make-or-break FDA decisions.
Clarus Ventures has unveiled a lead role in funding a startup, San Francisco-based Nuvelution Pharma, that has an eminent group of Big Pharma veterans on the board as it sets out to ink a few clinical trial deals with the industry.
The year's 10 highest-paid development executives pulled in $124.4 million in total compensation, a roughly 35% jump over 2013's top earners. And while each entrant benefited from meeting individual company goals, the whole group benefited from biopharma's macroeconomic moment in the sun, as the value of stock awards skyrocketed alongside the industry index.
GlaxoSmithKline is the first pharma company to get behind the U.K.'s forthcoming Francis Crick Institute, signing on to lend its minds and molecules to an open R&D effort.
Now that billionaire entrepreneur Patrick Soon-Shiong has taken control of tiny ConkWest and steered it toward a $173 million IPO, he's adding a makeover to the name that will fit more easily under the fast-growing NantWorks umbrella he's created.
Sequencing pioneer Lee Hood has already started enough biotechs to create his own cluster. And now he's taking another shot at the founding scientist's role, joining hands with a pair of high-profile biotech investment groups which are contributing a $36 million B round for a startup that has its sights set on nothing less than transforming healthcare--and our attitudes toward it.